FilingReader Intelligence

Sino Biopharmaceutical to present clinical trial data at ERS

August 25, 2025 at 05:01 PM UTC•By FilingReader AI

Sino Biopharmaceutical will present clinical data on three respiratory treatments at ERS 2025 in September-October.

TQC3721 has Breakthrough Therapy Designation in China and is in Phase III trials. TQC3403, a dual bronchodilator, anticipates marketing approval in early 2026 as China's first generic version.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

VOLUNTARY ANNOUNCEMENT - DATA FROM FOUR STUDIES OF "TQC3721 (PDE3/4 INHIBITOR)", "TQC2731 (TSLP MONOCLONAL ANTIBODY)" AND "TQC3403 (UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE POWDER FOR INHALATION)" PRESENTED AT ERS 2025August 25, 2025 at 10:38 AM UTC

Sino Biopharmaceutical

HKEX:1177•Hong Kong Exchange

RSS feed for Sino Biopharmaceutical

News Alerts

Get instant email alerts when Sino Biopharmaceutical publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →